Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
|
31335987 |
2020 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The MTT assay revealed that miR-130b modulated cell growth. qRT-PCR revealed an inverse correlation between miR-130b and PTEN in RCC.
|
31195398 |
2019 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of PTEN-Long in serum of patients with nephritis, renal cell carcinoma (RCC) as well as normal controls, and in serum and renal tissues of mice were measured by western blotting.
|
30680021 |
2019 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The expression pattern of tumor suppressor gene phosphatase and tensin homolog deleted on chromosome ten (PTEN) and phosphatase and tensin homolog deleted on chromosome ten/phosphatidylinositol3-kinase/protein kinase B (PTEN/PI3K/AKT) cell signaling pathway in renal cell carcinoma (RCC) were investigated in children.
|
30655739 |
2019 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The PTEN expressing RCC cell line A498 and the PTEN deficient 786-O cell line were stably transfected with the PTEN-Δ or PTEN transcript.
|
29954386 |
2018 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In summary, we conclude that DLX6-AS1 promotes renal cell carcinoma development via regulation of miR-26a/PTEN axis.
|
28881158 |
2017 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
This meta-analysis suggests that PTEN expression is of limited value in predicting the prognosis of patients with RCC for OS and PFS via immunohistochemistry staining analysis; and that for DSS, low PTEN expression is significantly associated with an unfavorable outcome.
|
28672019 |
2017 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Taken together, the findings indicated for the first time that miR-193a-3p functions as a tumor-promoting microRNA by directly targeting PTEN in renal cell carcinoma.
|
28639901 |
2017 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway.
|
27779645 |
2016 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study suggested that the miR-22/PTEN axis may be considered a novel therapeutic target in RCC.
|
27082730 |
2016 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
miR‑205 suppresses cell proliferation, invasion, and metastasis via regulation of the PTEN/AKT pathway in renal cell carcinoma.
|
27498834 |
2016 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
|
25401301 |
2015 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma.
|
25714556 |
2015 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Because loss of PTEN can activate mTOR and mTOR inhibitors are Food and Drug Administration approved to treat renal cell carcinoma, these agents have clinical potential in renal cell carcinoma associated with Cowden syndrome.
|
23764071 |
2013 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Relationship between PTEN and Livin expression and malignancy of renal cell carcinomas.
|
22938441 |
2012 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PHTS is a hereditary syndrome newly associated with pRCC, and PTEN IHC may be a helpful screening tool to identify pRCC patients with PHTS.
|
22381246 |
2012 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Another variant (rs701848) in the 3'UTR region of PTEN was associated with increased RCC risk (P = 0.014, OR = 1.45, 95%CI = 1.08-1.96, CC vs. TT); however, the association was not significant after adjusting for multiple comparisons.
|
23209702 |
2012 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The mTOR pathway showed widespread activation in RCC metastases of various sites with strong correlation between different components of this signaling cascade (P<.0001), but without significant PTEN genomic deletion.
|
20830770 |
2011 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Inactivated GSK3β, decreased PTEN expression and PAX2 positivity were observed in the vast majority of the multilocular cystic renal cell carcinomas.
|
21151099 |
2011 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, 19 of 20 advanced RCC showed somatic hypermethylation upstream of KILLIN, with the majority hypermethylated at more than one CpG island (13/19 vs. 3/23 with germline methylation, P < 0.0001). qRT-PCR revealed that methylation significantly downregulates KILLIN expression (P = 0.05), and demethylation treatment by 5-aza-2'deoxycytidine significantly increased KILLIN expression in all RCC cell lines while only increasing PTEN expression in one line.
|
21584899 |
2011 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
RGD |
Here, we have investigated the activity of PI 3-K and the expression of PTEN, p53, tuberin, p-mTOR, and p-p70S6K in both Eker rat RCC and human renal AML.
|
22737271 |
2011 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
|
19483472 |
2009 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aims of the present study were to determine the expression patterns of Akt pathway parameters PI3K, phosphatase and tensin homolog (PTEN), phosphor-Akt (p-Akt) and their combination, for their possible prognostic value in renal cell carcinoma (RCC).
|
18587247 |
2008 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
We concluded that a strong expression of PTEN in renal cell cancer did not block the PI3K-mediated phosphorylation of Akt in the tumour specimens analysed.
|
18425369 |
2008 |